Suspension of human autologous MSC 3P in 1.5 ml ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 2 | Amyotrophic lateral sclerosis | 1 |
2. Amyotrophic lateral sclerosis
Clinical trials : 645 / Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03828123 (ClinicalTrials.gov) | January 2012 | 20/7/2017 | Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis | A Prospective, Non-randomized, Open Label Study to Assess the Safety and the Efficacy of Autologous Multipotent Mesenchymal Stromal Cells in the Treatment of Amyotrophic Lateral Sclerosis | Motor Neuron Disease, Amyotrophic Lateral Sclerosis | Biological: Suspension of human autologous MSC 3P in 1.5 ml | Bioinova, s.r.o. | Department of Neurology, University Hospital Motol, Prague, Czech Republic | Completed | 18 Years | 65 Years | All | 26 | Phase 1/Phase 2 | NULL |